Treace Medical Concepts, Inc. (TMCI) is a Healthcare stock trading at $4.45 (as of 2026-08-20), with a market capitalization of $288.36M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Treace Medical Concepts, Inc. develops and sells orthopedic medical devices used by foot and ankle surgeons in the United States. Its offerings include the Lapiplasty procedure and the Lapiplasty Mini-Incision precision system, along with products for related procedures such as osteotomies, certain joint fusions, intercuneiform stabilization, and autograft bone harvesting.
Understand Treace Medical Concepts, Inc.: how it makes money
Treace Medical Concepts designs, manufactures, and markets orthopedic medical devices for foot and ankle surgeons in the United States, including its Lapiplasty procedure kit and Lapiplasty Mini-Incision precision system, generating revenue from selling these surgical systems and related products to surgeons.
Profitability is driven by how many surgeons actively perform Lapiplasty and how many Lapiplasty procedure kits each active surgeon uses, because revenue is tied to Lapiplasty procedure kit sales in the U.S. (tracked by Active Surgeons, Surgeon Utilization, and Average Lapoplasty Procedure Kits per Active Surgeon).
Business quality (Weak): The company reports a high gross margin (79.3%) but a deeply negative operating margin (-36.4%), suggesting substantial operating costs relative to current scale, so the key question is whether surgeon adoption and kit utilization can grow enough to lift operating leverage.
Bull case
Surgeon adoption footprint is measurable, with 3,300 active surgeons performing at least one Lapoplasty case and 6,459 Lapoplasty procedure kits sold: These metrics indicate the company has an installed base of surgeons using its technology.
Strong gross margin (79.3%) in the reported period: If operating cost discipline improves as volume scales, gross profit could translate more effectively into operating results.
Intellectual property development is ongoing, with 65 granted United States patents and 84 pending United States patent applications: A growing patent portfolio can support differentiation in bunion procedures.
Scale indicators from patients treated, including 100,000 patients treated with Lapoplasty out of 130,000 patients treated: A large share of treated patients using the core Lapoplasty technology supports product relevance.
Bear case
Operating margin is negative at -36.4% for the reported period: This indicates operating expenses are currently too high relative to the business, limiting profit generation even with strong gross margin.
Revenue and outcomes appear closely tied to surgeon utilization, with Surgeon Utilization at 10.1 and Average Lapoplasty Procedure Kits per Active Surgeon at 10.6: If utilization or kits per surgeon decline, revenue per active surgeon could weaken, putting pressure on operating leverage.
Adoption metrics show a still early market penetration, with Estimated United States Surgeon Penetration for Bunion Surgery at 29.0% and Estimated Market Penetration of Annual Bunion Surgical Procedures at 5.8%: Continued adoption is required, and progress depends on surgeon customers adopting new bunion technologies (including 20% surgeon customers adopting new bunion technologies).